BRVT221

BRVT221 is a novel anti-cancer drug candidate targeting a newly discovered mechanism for reprogramming cancer cells into normal cells, rather than directly killing them. The target was discovered by Professor Kwang-Hyun Cho's group at KAIST and represents an innovative approach to cancer therapy, aiming to manage cancer as a chronic disease with minimal side effects. This strategy could potentially maximize healthy lifespan by converting malignant cells back to normal phenotypes, offering a revolutionary alternative to traditional cytotoxic therapies. The development of BRVT221 is being pursued through collaboration between Biorevert and Oscotec[5].